Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
.png)
Dr Ferrer Biopharma team
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024.
This year, the Pharmapack Awards has built sustainability into each category as an aspect of consideration, highlighting the importance of considering sustainable practices and materials across every sector of the pharmaceutical industry. We sat down with Dr Ferrer Biopharma, winner of the Patient-Centric Design Award, to discuss how their GentleMist Technology utilises advanced fluid dynamics to enhance patient comfort and compliance when taking nasal sprays.
Please could you give a background to Dr Ferrer Biopharma and your overall mission as a company?
Our company was founded by clinicians’ experts in respiratory illness with the goal of bringing to the market high quality, evidence-based, consumer-focused and physician invented solutions that aim at maximising effectiveness while minimising side effects with a focus in patient’s experience. We see innovation development from the bedside to the bench, not the opposite.
Our mission is to bring to the market evidence-based therapies and drug delivery systems that combine new ideas with proven concepts in the service of helping people breathe better.
Your product GentleMist Technology builds on existing technologies to enhance patient comfort and compliance when using nasal sprays. How did you identify this technology as an area of improvement when considering patient centricity?
We identified the need for improvement in nasal drug delivery through extensive research and close collaboration with healthcare professionals and patients. Traditional nasal spray nozzles cause discomfort and hinder patient compliance due to the pressure exerted during administration and particle size. Recognising these challenges, GentleMist TechnologyTM (GMT) was designed with a plume geometry angle that delivers a gentle yet effective nasal spray pattern, eliminating discomfort and enhancing drug delivery precision.
What aspects of patient-centricity were considered when developing GentleMist Technology?
Patient-centricity is at the forefront of our development process. We conducted Human Factor studies and actively sought feedback from patients and clinicians throughout the product's creation. Surveys, focus groups, and direct interactions with patients played a pivotal role in shaping GentleMist Technology into a truly patient-centric solution. Their input guided us in fine-tuning the device and angle of application for optimal comfort and performance. Additionally, our collaboration with the exceptional team of engineers from our manufacturer partners at Bona and esteemed fluid dynamics scientists from renowned institutions ensured that GentleMist Technology’s innovation was grounded in rigorous research and scientific validation. This patient-centred approach resulted in a product that significantly improves comfort and treatment effectiveness.
How do events such as Pharmapack help companies like Dr Ferrer Biopharma contribute to a thriving pharmaceutical packaging industry?
Events like Pharmapack provide a valuable platform for companies like Dr Ferrer Biopharma to showcase our innovations and connect with industry experts, potential partners, and customers. These events foster collaboration and knowledge sharing that increases our exposure. At Pharmapack we can raise awareness about patient-centric solutions like GentleMist Technology, exchange ideas, and stay at the forefront of industry trends.
What does this award mean for a company like Dr Ferrer Biopharma?
Winning the Pharmapack Health Product Awards for Patient-Centric Design is a remarkable achievement and a validation of our unwavering commitment to patient-focused innovation. This prestigious award underscores the significant impact of GentleMist Technology and highlights our dedication to enhancing the lives of patients with upper respiratory conditions. It further solidifies our position in the industry.
What does the future hold for Dr Ferrer Biopharma and the GentleMist Technology?
With this award as a milestone, the future for Dr Ferrer Biopharma and GentleMist Technology is exceptionally promising. We are poised to expand the availability of GentleMist Technology across global markets, including increasing penetration in the US, Europe and Latin America. Our ongoing commitment to research and development remains steadfast, as we continuously strive to enhance our existing products and explore novel applications for our technology. Sustainability and eco-friendly practices will continue to be a top priority as we work diligently to reduce our environmental footprint. We are working GentleMist Technology fully recyclable, preservative-free and other applications. The journey ahead is filled with excitement, and we are eager to continue making a lasting impact on healthcare through our patient-centric solutions.
Discover all Pharmapack 2024 Award winners here.
Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance